1) KW-1062 was chiefly applied to 23 cases of various infectious diseases combined with underlying diseases, such as progressive cancer, diabetes mellitus and nosocomial infection due to resistant Staphylococcus aureus.
2) The clinical effectiveness rate of KW-1062 was 67% in all cases, and 50% in patients with urinary tract infections.
Bacteriological improvements were obtained in 64% of patients with respiratory tract infections and 60% in urinary tract infections.
3) Superinfection was observed in 8 cases in which appearance of fungi, gentamicin-resistant Pseudomonas aeruginosa, resistant Sta. aureus, etc. was noted.
4) Side effects were encountered in 7 cases (30%). Impaired sense of hearing or equilibrium was observed in 4 cases and hepatic impairment in one case.
No noticeable side-reactions were observed in renal function.
